Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Genmab
Woman and Man Max 99 years
Genmab A/S
Update Il y a 4 ans
A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had an inadequate response to TNF-α antagonist therapy Estudio Fase III, doble ciego, aleatorizado, controlado con placebo, de grupos paralelos, multicéntrico, para investigar la eficacia clínica de ofatumumab en pacientes adultos con artritis reumatoide activa y respuesta inadecuada a la terapia con antagonistas TNFα
To demonstrate efficacy of ofatumumab in reducing clinical signs and symptoms in adult RA patients after a single course of ofatumumab Demostrar la eficacia de ofatumumab para reducir los signos y sín...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Genmab A/S
Update Il y a 4 ans
A multicentre open-label, dose-escalation, trial of zanolimumab in combination with CHOP chemotherapy in subjects with CD4 positive non-cutaneous peripheral T-Cell Lymphoma with nodal involvement
To investigate safety and tolerability of ascending doses of zanolimumab up to 20mg/kg in combination with CHOP chemotherapy in order to define a maximum tolerated dose (MTD) in subjects with CD4 posi...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Genmab A/S
Update Il y a 4 ans
A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy and safety in adult patients with active rheumatoid arthritis receiving non-biologic background disease-modifying antirheumatic drugs
To demonstrate the efficacy of ofatumumab in reducing clinical signs and symptoms in adult RA patients after a single course of ofatumumab
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Genmab A/S
Update Il y a 4 ans
An open label clinical pilot study with local injection of human antibody (HuMax-Inflam) for the treatment of inflammatory psoriasis
The purpose of the study is to investigate whether treatment with HuMax-Inflam induces regression or reduces progression of inflammatory, progressive psoriasis in comparison with isotonic saline solut...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Genmab A/S
Update Il y a 4 ans
An Open label single arm trial investigating zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in combination with Best Supportive Care, in Patients with Non-Curable Squamous Cell Carcinoma of the Head and Neck who have Failed Standard Platinum-based Chemotherapy
To investigate zalutumumab in combination with BSC in terms of overall survival in non-curable patients with recurrent and/or metastatic disease who have failed after at least one course of standard-b...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Genmab
Update Il y a 4 ans
Genmab Hx-EGFr-203 : Essai de phase 1-2 en escalade de dose évaluant la tolérance d’un traitement associant zalutumumab à une radiochimiothérapie chez des patients ayant un cancer de la tête et du cou. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer la tolérance du zalutumumab lorsqu’il est associé à une radiochimiothérapie. Les patients inclus dans la phase 1 recevront un traitement comprenant une perfusion...
Country
France
organs
Tête et cou
Specialty
Radiothérapie et Chimiothérapie
,
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Genmab A/S
Update Il y a 4 ans
A double-blind, randomized, placebo-controlled, multi-center, Clinical Trial of ofatumumab, a fully human monoclonal anti-CD20 antibody in patients with moderate to severe stage Chronic Obstructive Pulmonary Disease
To evaluate efficacy of ofatumumab in decreasing inflammation in COPD assessed by bronchial biopsies.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Genmab
Update Il y a 4 ans
GENMAB GEN207 : Essai de phase 1-2 évaluant la tolérance puis l’efficacité d’un traitement associant le zalutumumab à la radiothérapie, chez des patients ayant un carcinome à cellules squameuses de la tête et du cou. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
An open-label, international, multi-center, phase I/II, dose-escalation trial investigating the safety of zalutumumab, a human monoclonal epidermal growth factor receptor antibody in combination with ...
Country
France
organs
Tête et cou
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man
Between 18 years
and 99 years
Genmab
Update Il y a 4 ans
Genmab GEN415 : Essai de phase 2 évaluant l’efficacité d’un traitement par ofatumumab chez des patients ayant un lymphome. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
An open-label, single-arm. multi-center phase 2 trial with ofatumumab in patients with relapsed diffuse large B-cell lymphoma (DLBCL) ineligible for transplant or relapsed after autologous transplant.
Country
France
organs
Lymphomes non hodgkinien
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man
Between 18 years
and 99 years
Genmab
Update Il y a 4 ans
Genmab Hx-CD20-405 : Essai de phase 3 randomisé, en double aveugle, comparant 2 doses d’un traitement par ofatumumab chez des patients ayant un lymphome folliculaire. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est de comparer deux doses d’un traitement par ofatumumab chez des patients ayant un lymphome folliculaire. Les patients seront répartis de façon aléatoire en deux groupes de ...
Country
France
organs
Lymphomes non hodgkinien
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
1
2
3
Next